Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 3
1970 1
1971 3
1972 1
1974 2
1975 4
1976 6
1977 2
1978 7
1980 7
1981 7
1982 3
1983 6
1984 3
1985 4
1986 6
1987 3
1988 4
1989 3
1990 3
1991 2
1992 1
1993 2
1994 4
1995 4
1996 1
1997 4
1998 1
2000 2
2001 2
2003 1
2004 3
2006 1
2007 2
2008 2
2010 2
2011 1
2012 1
2013 1
2014 1
2017 2
2018 3
2019 1
2021 1
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean g modes (10,640 results)?
Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
Lichner Z, Saleeb R, Butz H, Ding Q, Nofech-Mozes R, Riad S, Farag M, Varkouhi AK, Dos Santos CC, Kapus A, Yousef GM. Lichner Z, et al. FASEB J. 2019 Jan;33(1):1347-1359. doi: 10.1096/fj.201800596R. Epub 2018 Aug 27. FASEB J. 2019. PMID: 30148679
In summary, we suggest that sunitinib-resistant RCC cells exist in treatment-sensitive tumors and are histologically identifiable.-Lichner, Z., Saleeb, R., Butz, H., Ding, Q., Nofech-Mozes, R., Riad, S., Farag, M., Varkouhi, A. K., dos Santos, C. C., Kapus, A., Yousef, …
In summary, we suggest that sunitinib-resistant RCC cells exist in treatment-sensitive tumors and are histologically identifiable.-Lichner, …
Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases.
Tankersley DL. Tankersley DL. Immunol Rev. 1994 Jun;139:159-72. doi: 10.1111/j.1600-065x.1994.tb00861.x. Immunol Rev. 1994. PMID: 7927410 Review.
Experimental animal models of autoimmune disease, such as the mouse model for systemic lupus erythematosus (Mozes et al. 1993), might be very useful in this regard. Finally, it needs to be emphasized that the usefulness of high doses of Igi.v. in many autoimmune diseases r …
Experimental animal models of autoimmune disease, such as the mouse model for systemic lupus erythematosus (Mozes et al. 1993), might …
Genetic control of HLA-linked immune responsiveness to (H,G)-A-L.
Katz D, Suez D, Brautbar C, Cohen T, Bentwich Z, Mozes E. Katz D, et al. Hum Immunol. 1986 Jan;15(1):75-84. doi: 10.1016/0198-8859(86)90318-6. Hum Immunol. 1986. PMID: 2936703
Fifty-three donors belonging to seven families were tested for their immune response potential to (H,G)-A-L. Most of these donors had been previously tested for their ability to respond to (T,G)-A-L and were all HLA typed as well. ...The different patterns of respon …
Fifty-three donors belonging to seven families were tested for their immune response potential to (H,G)-A-L. Most of these donors had …
Dichotomy between the T and the B cell epitopes of the synthetic polypeptide (T,G)-A--L.
Zisman E, Sela M, Ben-Nun A, Mozes E. Zisman E, et al. Eur J Immunol. 1994 Oct;24(10):2497-505. doi: 10.1002/eji.1830241036. Eur J Immunol. 1994. PMID: 7523144
Thus, we were interested to elucidate the major T cell epitope of (T,G)-A--L, by using the ordered polypeptides (T-T-G-G)-A--L and (T-G-T-G)-A--L, in which only the two internal amino acids of the tetrapeptide attached to the side chains are swi …
Thus, we were interested to elucidate the major T cell epitope of (T,G)-A--L, by using the ordered polypeptides (T-T-G-G …
The genetic control of antibody specificity.
Mozes E, McDevitt HO, Jaton JC, Sela M. Mozes E, et al. J Exp Med. 1969 Dec 1;130(6):1263-78. doi: 10.1084/jem.130.6.1263. J Exp Med. 1969. PMID: 4187525 Free PMC article.
F(1) x DBA/1 backcross anti-(Phe, G)-Pro--L sera segregate in their ability to bind (T,G)-Pro--L, and there is no linkage of anti-(T,G)-Pro--L binding capacity with the H-2(s) allele of the SJL grandparent. F(1) x SJL anti-(Phe, G)-Pro-L sera segregate …
F(1) x DBA/1 backcross anti-(Phe, G)-Pro--L sera segregate in their ability to bind (T,G)-Pro--L, and there is no linkage of a …
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E, Sharabi A. Mozes E, et al. Autoimmun Rev. 2010 Nov;10(1):22-6. doi: 10.1016/j.autrev.2010.07.004. Epub 2010 Jul 23. Autoimmun Rev. 2010. PMID: 20659591 Review.
The beneficial effects were associated with a diminished production of pathogenic cytokines (e.g. IFN-gamma, IL-10, and IL-1beta) and with increased production of the immunosuppressive cytokine, TGF-beta. ...
The beneficial effects were associated with a diminished production of pathogenic cytokines (e.g. IFN-gamma, IL-10, and IL-1beta) and …
Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
Sthoeger Z, Sharabi A, Mozes E. Sthoeger Z, et al. J Autoimmun. 2014 Nov;54:60-71. doi: 10.1016/j.jaut.2014.06.002. Epub 2014 Jun 21. J Autoimmun. 2014. PMID: 24958634 Review.
In addition to the non-antigen specific agents that may affect the normal immune system as well, SLE-specific therapeutic means are under development. These are synthetic peptides (e.g. pConsensus, nucleosomal peptides, P140 and hCDR1) that are sequences of conserved regio …
In addition to the non-antigen specific agents that may affect the normal immune system as well, SLE-specific therapeutic means are under de …
Specificity of genes controlling immune responsiveness to (T,G)-A--L and (Phe,G)-A--L.
Lifshitz R, Schwartz M, Mozes E. Lifshitz R, et al. Immunology. 1980 Oct;41(2):339-46. Immunology. 1980. PMID: 6777289 Free PMC article.
Mice possessing the H-2b haplotype are high responders to the cross-reactive antigens (T,G)-A--L and (Phe,G)-A--L whereas mice with the H-2k haplotype respond only to (Phe,G)-A--L. ...Only (Phe,G)-A--L primed and boosted H-2k mice produced high levels …
Mice possessing the H-2b haplotype are high responders to the cross-reactive antigens (T,G)-A--L and (Phe,G)-A--L whereas mice …
Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE.
Shoenfeld Y, Mozes E. Shoenfeld Y, et al. FASEB J. 1990 Jun;4(9):2646-51. doi: 10.1096/fasebj.4.9.2140806. FASEB J. 1990. PMID: 2140806 Review.
The disease is characterized clinically (proteinuria), serologically (e.g., anti-dsDNA, anti-Sm antibodies), and by pathological findings (e.g., deposition of 16/6 Id in the kidneys). ...
The disease is characterized clinically (proteinuria), serologically (e.g., anti-dsDNA, anti-Sm antibodies), and by pathological find …
Specificity and crossreactivity of idiotypes of murine antibodies induced by poly(Tyr,Glu)-poly(DLAla)-poly(Lys) and poly(Phe,Glu)-poly(DLAla)-poly(Lys).
Lifshitz R, Schwartz M, Mozes E. Lifshitz R, et al. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5118-21. doi: 10.1073/pnas.75.10.5118. Proc Natl Acad Sci U S A. 1978. PMID: 84385 Free PMC article.
However, while the binding to (T,G)-A-L could be inhibited completely with the two antigens, the binding to (Phe,G)-A-L was inhibited completely with (Phe,G)-A-L and only partially with (T,G)-A-L. ...(T,G)-A-L specific antibodies were purified o …
However, while the binding to (T,G)-A-L could be inhibited completely with the two antigens, the binding to (Phe,G)-A-L was in …
121 results